Summary Garvan Institute of Medical Research (Garvan Institute) is a biomedical research institute.The institute conducts research in the fields of cancer, diabetes and obesity, Alzheimer’s and Parkinson’s disease, asthma, rheumatoid arthritis, osteoporosis, arthritis and pituitary disorders.
It also conducts research in various different types of cancer such as breast cancer, prostate cancer, lung cancer, colorectal cancer, ovarian cancer and pancreatic cancer.Garvan Institute’s immunology research includes asthma, type 1 diabetes, rheumatoid arthritis, lupus, Sjogren’s syndrome and autoimmune hepatitis, among others.
The institute’s research capabilities comprise animal imaging, animal research, bioinformatics, flow cytometry, functional genomics, genome editing, biodata visualisation, and others. Garvan Institute is headquartered in Darlinghurst, New South Wales, Australia.
Garvan Institute of Medical Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Myc Proto Oncogene Protein - Drugs In Development, 2021 Summary Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 23 molecules. Out of which approximately 18 molecules are developed by companies and remaining...
Executive Summary Global Radiotherapy Market was valued at USD 7987.01 Million in the year 2020. Increasing healthcare expenditure on the back of growing disposable income, rapid technological advancements along with high prevalence of cancer is expected to drive the radiotherapy market significantly. Further, expanding...
Fallopian Tube Cancer (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Drugs In Development, 2021, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.Fallopian tube cancer is also...
The ablation technology market is projected to reach USD 8.1 Billion by 2026 from USD 5.2 Billion in 2021, at a CAGR of 9.3% during the forecast period. The growing elderly population has also driven the incidence of target conditions and contributed to the demand for effective treatment. However, the reuse and reprocessing of devices in developed...
Report Scope: This report aims to provide a comprehensive study of the global market for oncology pharmaceuticals (cancer drugs).It provides a detailed description of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and current and historical market revenues. The...
histopathology services market was valued at US$ 35,187.90 million by 2028 from US$ 23,890.44 million in 2021; it is expected to grow at a CAGR of 5.7% from 2021 to 2028. Factors such as rising demand for biologics and increasing prevalence of chronic diseases are driving the growth of the histopathology services market. However, limitations...
The global nuclear medicine market is projected to reach USD 7.5 billion by 2026 from USD 4.8billion in 2021, at a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the...
Global Precision Medicine Market, By Products & Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, NGS, Others), By Application (Oncology, Cardiology, Respiratory,...
The global esoteric testing market is projected to reach USD 36.3 billion by 2026 from USD 21.0 billion in 2021, at a CAGR of 11.6% during the forecast period. Market growth is largely driven by the rising incidence of chronic and infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.